2-(2-Bromoacetyl)-3-methoxy-9,9-dimethyl-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4-one | 1289648-88-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2-Bromoacetyl)-3-methoxy-9,9-dimethyl-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4-one
• CAS: 1289648-88-9
• 化学式: C₁₂H₁₅BrN₂O₄
• 分子量: 331.166
• InChiKey: XYYLIHXWLLXJEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  68.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-Bromoacetyl)-3-methoxy-9,9-dimethyl-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4-one 在 三溴化硼-二甲基硫醚 三溴甲基硫化硼 、 sodium hydride 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 、 mineral oil 为溶剂， 反应 9.0h， 生成 2-(1-(4-fluorobenzyl)-1H-imidazol-4-yl)-3-hydroxy-9,9-dimethyl-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one
  参考文献：
  名称：

  [EN] HIV INTEGRASE INHIBITORS
  [FR] INHIBITEURS DE L'INTÉGRASE DU VIH

  摘要：

  该披露通常涉及到式I的新化合物，包括它们的盐，这些化合物抑制HIV整合酶并阻止病毒整合到人类DNA中。这种作用使得这些化合物对治疗HIV感染和艾滋病有用。该发明还涵盖了用于治疗HIV感染者的药物组合物和方法。

  公开号：

  WO2011046873A1
• 作为产物：
  描述：

  3-羟基-9,9-二甲基-4-氧代-4,6,7,9-四氢嘧啶并[2,1-C][1,4]噁嗪-2-羧酸乙酯 在 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 、 sodium hydroxide 、 copper(ll) bromide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 苯 为溶剂， 反应 56.5h， 生成 2-(2-Bromoacetyl)-3-methoxy-9,9-dimethyl-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4-one
  参考文献：
  名称：

  Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors

  摘要：

  A series of heterocyclic pyrimidinedione-based HIV-1 integrase inhibitors was prepared and screened for activity against purified integrase enzyme and/or viruses modified with the following mutations within integrase: Q148R, Q148H/G140S and N155H. These are mutations that result in resistance to the first generation integrase inhibitors raltegravir and elvitegravir. Based on consideration of drug-target interactions, an approach was undertaken to replace the amide moiety of the first generation pyrimidinedione inhibitor with azole heterocycles that could retain potency against these key resistance mutations. An imidazole moiety was found to be the optimal amide substitute and the observed activity was rationalized with the use of calculated properties and modeling. Rat pharmacokinetic (PK) studies of the lead imidazole compounds demonstrated moderate clearance and moderate exposure.

  DOI：

  10.1016/j.bmcl.2019.126784

文献信息

• [EN] HIV INTEGRASE INHIBITORS<br/>[FR] INHIBITEURS DE L'INTÉGRASE DU VIH
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011046873A1

  公开（公告）日：2011-04-21

  The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

  该披露通常涉及到式I的新化合物，包括它们的盐，这些化合物抑制HIV整合酶并阻止病毒整合到人类DNA中。这种作用使得这些化合物对治疗HIV感染和艾滋病有用。该发明还涵盖了用于治疗HIV感染者的药物组合物和方法。
• HIV Integrase Inhibitors
  申请人：Naidu B. Narasimhulu

  公开号：US20110245241A1

  公开（公告）日：2011-10-06

  The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

  该披露通常涉及到公式I的新化合物及其盐，这些化合物抑制HIV整合酶并防止病毒整合到人类DNA中。这种作用使化合物对治疗HIV感染和艾滋病有用。该发明还包括用于治疗HIV感染者的药物组合物和方法。
• US8383639B2
  申请人：——

  公开号：US8383639B2

  公开（公告）日：2013-02-26
• Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors
  作者：Kevin M. Peese、B. Narasimhulu Naidu、Manoj Patel、Chen Li、David R. Langley、Brian Terry、Tricia Protack、Volodymyr Gali、Zeyu Lin、Himadri K. Samanta、Ming Zheng、Susan Jenkins、Ira B. Dicker、Mark R. Krystal、Nicholas A. Meanwell、Michael A. Walker

  DOI：10.1016/j.bmcl.2019.126784

  日期：2020.2

  A series of heterocyclic pyrimidinedione-based HIV-1 integrase inhibitors was prepared and screened for activity against purified integrase enzyme and/or viruses modified with the following mutations within integrase: Q148R, Q148H/G140S and N155H. These are mutations that result in resistance to the first generation integrase inhibitors raltegravir and elvitegravir. Based on consideration of drug-target interactions, an approach was undertaken to replace the amide moiety of the first generation pyrimidinedione inhibitor with azole heterocycles that could retain potency against these key resistance mutations. An imidazole moiety was found to be the optimal amide substitute and the observed activity was rationalized with the use of calculated properties and modeling. Rat pharmacokinetic (PK) studies of the lead imidazole compounds demonstrated moderate clearance and moderate exposure.